CICL-1 (L829)
Version 1.dac2bcd9 · 2026-09-13
| CAS No. | Not available |
| Chemical Name | CICL-1 (L829) |
| Synonyms | L-829, L 829, Capstan-lipid-CICL-1, Capstanlipid CICL1, CICL1, CICL 1, CICL-1, Lipid 829, L-829, L 829, Compound A-11, DC60860 |
| SMILES | CCCCCCCCC(=O)OCC(COC(=O)CCCCCCCC)CC(=O)OCCN(CCOC(=O)CC(COC(=O)CCCCCCCC)COC(=O)CCCCCCCC)C(=O)OCCN(C)C |
| Formula | C55H100O14N2 |
| M.Wt | 1,013.40 |
| Purity | >98% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Hunter TL, Bao Y, Zhang Y, et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science. 2025;388(6753):1311-1317. |
CICL-1, identified in the cited study as Lipid 829 (L829), is an ionizable lipid used in targeted lipid nanoparticles for in vivo delivery of CAR mRNA to T cells. CD8-targeted L829 tLNPs preferentially engineered CD8-positive T cells in the reported models, produced rapid B-cell depletion, and controlled a humanized leukemia xenograft. In cynomolgus monkeys, anti-CD20 CAR mRNA tLNPs produced deep peripheral and tissue B-cell depletion, followed by repopulation dominated by naïve B cells; the authors described this finding as suggestive of immune reset. The supplied main article does not include Supplementary Table S1, so the complete five-lipid composition and N/P ratio are not presented as verified formulation values. All performance statements below are literature-reported study results, not product specifications or guaranteed outcomes.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →